<doc>
  <docmeta id="113hr3877ih">
    <bill congress="113" type="hr" number="3877" version="ih"/>
    <revision size="6048" annotations="0" status="complete" id="4" commit-time="2014-01-24T23:18:51Z" committer="mbohmer" doc="113hr3877ih/4.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HB8AE841F59D8457081A75B3FA48985D4" public-private="public">
  <metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 3877 IH: Lymphedema Treatment Act</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-01-15</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code>
    <congress>113th CONGRESS</congress>
    <session>2d Session</session>
    <legis-num>H. R. 3877</legis-num>
    <current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
    <action>
      <action-date date="20140115">January 15, 2014</action-date>
      <action-desc>
        <sponsor name-id="R000578">Mr. Reichert</sponsor> (for himself, <cosponsor name-id="B000574">Mr. Blumenauer</cosponsor>, <cosponsor name-id="L000567">Mr. Lance</cosponsor>, and <cosponsor name-id="B001259">Mr. Braley of Iowa</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc>
    </action>
    <legis-type>A BILL</legis-type>
    <official-title>To amend title XVIII of the Social Security Act to provide for Medicare coverage of certain lymphedema compression treatment items as items of durable medical equipment.</official-title>
  </form>
  <legis-body id="HF445847DDECD413B81AFF7FA1D20D18C" style="OLC">
    <section id="HD3485329A6AD45C6A499152338080F65" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>Lymphedema Treatment Act</short-title>
        </quote>.</text>
    </section>
    <section id="H64F173574813436AA0FF9144579A9BB3">
      <enum>2.</enum>
      <header>Findings</header>
      <text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> makes the following findings:</text>
      <paragraph id="H5404083451BB4F5F993E14E75C1519D9">
        <enum>(1)</enum>
        <text display-inline="yes-display-inline">Lymphedema is a chronic disease that results in an accumulation of protein-rich lymph fluid in parts of the body where lymph nodes or lymphatic vessels are damaged or inadequate.</text>
      </paragraph>
      <paragraph id="HE2A42CA873A249639C2185449440E87F">
        <enum>(2)</enum>
        <text>Lymphedema afflicts millions of Americans, including men, women, and children who can be born with a primary form of lymphedema. The majority of cases, however, are secondary forms of lymphedema most often caused by cancer treatments that damage the body’s lymph transport and immune functions.</text>
      </paragraph>
      <paragraph id="HC8C198B6636140479D38AAFEE8D351E7">
        <enum>(3)</enum>
        <text display-inline="yes-display-inline">A 2010 peer-reviewed study in the American Cancer Society’s Cancer journal stated <quote>lymphedema is a common post-treatment condition [and] has been described as one of the most significant survivorship issues</quote>. The study reported an overall cancer-related lymphedema incidence rate of 15.5 percent, with specific rates as follows: sarcoma 30 percent, breast 20 percent, gynecological 20 percent, melanoma 16 percent, genital-urinary 10 percent, and head and neck 4 percent. Risk increased 22 percent after pelvic lymph node removal and 31 percent after radiation therapy.</text>
      </paragraph>
      <paragraph id="H7CE3636264D047ACB6B0930E35F7E6F2">
        <enum>(4)</enum>
        <text>Lymphedema is progressive when left untreated or under-treated and can put patients at greater risk for serious infections or other costly complications.</text>
      </paragraph>
      <paragraph id="HD57BAC77037248F78E4D65001DFDD6AE">
        <enum>(5)</enum>
        <text>
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> acknowledged the importance of comprehensive lymphedema treatment coverage with passage of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Women’s Health and Cancer Rights Act of 1998">Women’s Health and Cancer Rights Act of 1998</cato:entity-ref>, which requires group health plans, insurance companies, and health maintenance organizations to cover breast cancer-related lymphedema treatment post mastectomy and reconstruction.</text>
      </paragraph>
      <paragraph id="H4B9A5F32544C4476BD34AA8D1EA9D114">
        <enum>(6)</enum>
        <text>Medicare beneficiaries with lymphedema currently lack coverage for compression therapy, an essential component of care they must use to manage their chronic disease. As a result, many patients cannot maintain their condition and experience an unnecessary loss of health and of function in the activities of daily living.</text>
      </paragraph>
      <paragraph id="H0E6DB0CCC8964375BCF04147D2683E80">
        <enum>(7)</enum>
        <text>This Medicare coverage gap should be closed to help provide improved health care for lymphedema patients and in turn decrease the incidence of costly complications, co-morbidities and related disabilities.</text>
      </paragraph>
    </section>
    <section id="HEBC203CB07DD49288A533C111AB07B54">
      <enum>3.</enum>
      <header>Medicare coverage of certain lymphedema compression treatment items as items of durable medical equipment</header>
      <subsection id="H73FD80C93E3F420CA057B1D0B54D8F11">
        <enum>(a)</enum>
        <header>In general</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Social Security Act/s:1861">Section 1861 of the Social Security Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">
            <cato:entity-ref entity-type="uscode" value="usc/42/1395x">42 U.S.C. 1395x</cato:entity-ref>
          </external-xref>)</cato:entity> is amended—</text>
        <paragraph id="HA4403ED950BE4B31AE993EA06D83F194">
          <enum>(1)</enum>
          <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1861/ss:n">subsection (n)</cato:entity-ref>, in the first sentence, by inserting before the semicolon the following: <quote>and includes lymphedema compression treatment items (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1861/ss:iii" proposed="true">subsection (iii)</cato:entity-ref>)</quote>; and</text>
        </paragraph>
        <paragraph id="HE1A89A60A3FE479DB45CB3800F2E0B89">
          <enum>(2)</enum>
          <text>by adding at the end the following new subsection:</text>
          <quoted-block display-inline="no-display-inline" id="H7CBF4843BB7E4D3DAD440B58C0AC71B2" style="OLC">
            <subsection display-inline="no-display-inline" id="HACA009EBD55E4B45A4ECD108859304F9">
              <enum>(iii)</enum>
              <header>Lymphedema compression treatment items</header>
              <text display-inline="yes-display-inline">The term <term>lymphedema compression treatment items</term>—</text>
              <paragraph id="HF57DD69733884DCE875E40FE43C5375F">
                <enum>(1)</enum>
                <text>means, with respect to an individual, compression garments, devices, bandaging systems, components, and supplies—</text>
                <subparagraph id="HC50F9B5D891E4489B8956C5DB59D344A">
                  <enum>(A)</enum>
                  <text>that are primarily and customarily used in the medical treatment of lymphedema;</text>
                </subparagraph>
                <subparagraph id="H0E75ACF9653B4888AD7EF3E729380153">
                  <enum>(B)</enum>
                  <text>as prescribed by a physician (or a physician assistant, nurse practitioner, or a clinical nurse specialist (as those terms are defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1861/ss:aa/p:5">section 1861(aa)(5)</cato:entity-ref>) to the extent authorized under State law); and</text>
                </subparagraph>
                <subparagraph id="HE6DBD597E34B4BC69E656CCF41096974">
                  <enum>(C)</enum>
                  <text>which would not, other than under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/s:1861/ss:s/p:6">subsection (s)(6)</cato:entity-ref>, be included as medical and other health services under this title; and</text>
                </subparagraph>
              </paragraph>
              <paragraph id="H5ABDF533E5D34D0BA5EFDBF360782755">
                <enum>(2)</enum>
                <text>includes—</text>
                <subparagraph id="HE5FBF25C29974E1CB038437A2066C6AF">
                  <enum>(A)</enum>
                  <text>multilayer compression bandaging systems;</text>
                </subparagraph>
                <subparagraph id="H0EE3CA580D8B49039B12CFF5AC97ADC4">
                  <enum>(B)</enum>
                  <text>custom or standard fit gradient compression garments;</text>
                </subparagraph>
                <subparagraph id="HF3C175C6284647CCBDB99311BEEA8055">
                  <enum>(C)</enum>
                  <text>non-elastic and low-elastic compression garments and compression wraps and directional flow pads; and</text>
                </subparagraph>
                <subparagraph id="HC0A65BECBF0F485589BBACBB5F9A2E33">
                  <enum>(D)</enum>
                  <text>any other compression garments, bandaging systems, devices, and aids determined by the Secretary to be effective in the prevention or treatment of lymphedema.</text>
                </subparagraph>
              </paragraph>
            </subsection>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph>
      </subsection>
      <subsection id="H6AA70B3225574B54822384A12983C5E3">
        <enum>(b)</enum>
        <header>Effective date</header>
        <text>The amendment made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Lymphedema Treatment Act/s:3/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall apply to lymphedema compression treatment items furnished on or after 180 days after the date of the enactment of this Act.</text>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>